Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Schizophrenia

Schizophrenia

Subtypes of Schizophrenia

Cognitive impairment associated with schizophrenia 1 Schizophrenia-Spectrum Psychosis 1 First-episode schizophrenia 0 Schizotypal personality disorder 0

84 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Schizophrenia

594 trials tracked for Schizophrenia: 271 in phase 3 or 4 and 77 with published results. The most-cited published study has 279 citations.

594Trials tracked
271Phase 3 & 4
0Recruiting
77With published results
Phase distribution
Phase 4 116 Phase 3 155 Phase 2 111 Phase 1 46 Other / NA 166
  1. Phase 3 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Completed · 279 cited
  2. Phase 4 Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia Completed · 255 cited
  3. Phase 4 Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia Completed · 255 cited
  4. Phase 4 The Effects of Nicotine on Cognition in Schizophrenia Completed · 239 cited
  5. Phase 3 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2) Completed · 217 cited
  6. Phase 3 Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia Completed · 205 cited
Show 44 more trials
  1. Phase 4 Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics Completed · 200 cited
  2. Phase 4 Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia Completed · 172 cited
  3. Phase 4 Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia Completed · 170 cited
  4. Phase 3 Safety and Efficacy of Cariprazine in Patients With Schizophrenia Completed · 168 cited
  5. Phase 3 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) Completed · 157 cited
  6. Phase 4 Varenicline Adjunctive Treatment in Schizophrenia Completed · 141 cited
  7. Phase 4 Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis Completed · 111 cited
  8. Phase 4 Varenicline Effects In Schizophrenic Smokers Completed · 106 cited
  9. Phase 4 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed · 103 cited
  10. Phase 3 A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia Completed · 100 cited
  11. Phase 3 Long-term Study of Cariprazine in Patients With Schizophrenia Completed · 84 cited
  12. Phase 4 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy Completed · 72 cited
  13. Phase 4 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Completed · 72 cited
  14. Phase 3 Safety and Efficacy of Cariprazine in Schizophrenia Completed · 69 cited
  15. Phase 3 Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia Completed · 66 cited
  16. Phase 4 Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia Completed · 65 cited
  17. Phase 3 A Study of Paliperidone Palmitate 6-Month Formulation Completed · 61 cited
  18. Phase 3 A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) Completed · 54 cited
  19. Phase 4 Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Completed · 53 cited
  20. Phase 3 A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) Completed · 52 cited
  21. Phase 4 Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder Completed · 37 cited
  22. Phase 3 Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Completed · 31 cited
  23. Phase 3 Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia Completed · 30 cited
  24. Phase 3 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia Completed · 28 cited
  25. Phase 3 Relapse Prevention Study in Patients With Schizophrenia Completed · 28 cited
  26. Phase 4 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia Completed · 27 cited
  27. Phase 4 Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia Completed · 27 cited
  28. Phase 3 Long-term Study of DSP-5423P in Patients With Schizophrenia Completed · 24 cited
  29. Phase 3 A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) Completed · 24 cited
  30. Phase 3 Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia. Completed · 23 cited
  31. Phase 3 A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia Completed · 20 cited
  32. Phase 3 Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension Completed · 20 cited
  33. Phase 3 Tryptophan MRI in People With Schizophrenia and Healthy Controls Completed · 19 cited
  34. Phase 4 A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic Completed · 17 cited
  35. Phase 3 Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder Completed · 15 cited
  36. Phase 3 A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform Completed · 14 cited
  37. Phase 3 Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia Completed · 12 cited
  38. Phase 3 Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia Completed · 12 cited
  39. Phase 3 Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia Completed · 12 cited
  40. Phase 3 Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia Completed · 12 cited
  41. Phase 3 A Physical Dependence Study in Schizophrenia Completed · 11 cited
  42. Phase 3 Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients Completed · 11 cited
  43. Phase 3 Pediatric Open-Label Extension Study Completed · 11 cited
  44. Phase 3 A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia Completed · 11 cited

Showing the 50 most-cited and recently-updated of 594 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Diabetes and social support associations with cognitive impairment in elderly schizophrenia inpatients
Psychiatry Cohort
Diabetes and social support associations with cognitive impairment in elderly schizophrenia inpatients Social support and daily living skills linked to lower dementia risk in schizophrenia
This retrospective cross-sectional study of 149 elderly inpatients with schizophrenia found a 47.7% prevalence of cognitive impairment.
Nearly half of elderly schizophrenia patients have cognitive impairment. Social support and daily living skills may protect against it.
Frontiers Apr 30, 2026
Systematic review and meta-analysis finds 50% prevalence of antipsychotic polypharmacy in MENAT/EMRO countries
Psychiatry Meta-analysis
Systematic review and meta-analysis finds 50% prevalence of antipsychotic polypharmacy in MENAT/EMRO countries Half of Schizophrenia Patients Take Multiple Drugs at Once
This systematic review and meta-analysis of 17 studies (6,053 individuals) from MENAT/EMRO countries found a pooled prevalence of antipsycho…
New data reveals half of patients with schizophrenia in the Middle East take multiple antipsychotic drugs at once.
Frontiers Apr 29, 2026
Longer untreated psychosis linked to less symptom improvement in first-episode schizophrenia
Psychiatry Cohort
Longer untreated psychosis linked to less symptom improvement in first-episode schizophrenia Shorter Untreated Psychosis Linked to Better Recovery in Schizophrenia
This cohort study of 99 first-episode schizophrenia patients found that longer duration of untreated psychosis (DUP >26 weeks) was associate…
Patients who get care sooner for first-episode schizophrenia show greater symptom improvement than those who wait longer.
Frontiers Apr 29, 2026
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults
Psychiatry FDA Approval
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults FDA approves Caplyta to treat schizophrenia in adults
FDA approved Caplyta (lumateperone) for treatment of schizophrenia in adults.
The FDA approved Caplyta (lumateperone) for treating schizophrenia in adults.
FDA Apr 29, 2026
Narrative review explores microbiome mechanisms as a promising adjunctive avenue for managing depression, anxiety, bipolar disorder, and schizophrenia
Psychiatry Sys. Review
Narrative review explores microbiome mechanisms as a promising adjunctive avenue for managing depression, anxiety, bipolar disorder, and schizophrenia Gut Bacteria Can Change Your Mood
This narrative review examines how microbiome-driven modulation of neurotransmitters, microbial metabolites, immune activation, and vagal ne…
What if the bacteria in your gut could be quietly shaping how you feel every day — and fixing them could ease anxiety or depression?
Frontiers Apr 28, 2026
Observational study identifies sensory perception differences in schizophrenia and first-episode psychosis
Psychiatry
Observational study identifies sensory perception differences in schizophrenia and first-episode psychosis Simple tests reveal unique sensory signs for early psychosis types
This observational study investigated psychophysical differences in pictorial size perception and auditory discomfort among patients with sc…
New low-cost tests can spot unique sensory changes that help doctors tell schizophrenia apart from bipolar disorder in early psychosis cases…
medRxiv Apr 28, 2026
Parental severe mental illness associated with reduced offspring cognitive and academic performance in large meta-analysis
Psychiatry Meta-analysis
Parental severe mental illness associated with reduced offspring cognitive and academic performance in large meta-analysis Children of parents with mental illness face real cognitive hurdles now
This meta-analysis examined 1,586,339 offspring of parents with severe mental illnesses, including schizophrenia, bipolar disorder, and majo…
New research shows kids of parents with severe mental illness struggle with memory and thinking skills, but early help can make a big differ…
Apr 27, 2026
VR-CBTp and CBTp Outcomes for Schizophrenia Spectrum Disorders Paranoia in 254-Person RCT
Psychiatry RCT
VR-CBTp and CBTp Outcomes for Schizophrenia Spectrum Disorders Paranoia in 254-Person RCT Virtual reality therapy helps some schizophrenia patients more than standard talk therapy
This randomized controlled trial involved 254 individuals with schizophrenia spectrum disorders comparing 10-session VR-CBTp to standard CBT…
People with schizophrenia who struggle with motivation or stronger delusions may benefit more from VR therapy than standard talk therapy.
Apr 27, 2026
ADHD and ASD polygenic risk scores correlate with antipsychotic responsiveness in schizophrenia postmortem brains
Psychiatry Cohort
ADHD and ASD polygenic risk scores correlate with antipsychotic responsiveness in schizophrenia postmortem brains Genes for ADHD and Autism May Predict Schizophrenia Drug Response
This postmortem brain study in 24 patients with schizophrenia and 48 controls examined polygenic risk scores for ADHD and ASD.
Genes tied to ADHD and autism may predict how well antipsychotic drugs work in schizophrenia patients.
Frontiers Apr 27, 2026
Observational study identifies cortical organization and topological alterations in schizophrenia
Psychiatry
Observational study identifies cortical organization and topological alterations in schizophrenia New Brain Maps Show Two Distinct Types of Schizophrenia
This observational study abstract examines cortical organization and subtyping in 3,958 individuals with schizophrenia compared to 5,489 neu…
New brain scans reveal two distinct patterns in schizophrenia that could lead to better personalized care for patients with the condition.
medRxiv Apr 27, 2026
Narrative review proposes connectomic-guided psychosurgery framework for treatment-refractory patients
Psychiatry Sys. Review
Narrative review proposes connectomic-guided psychosurgery framework for treatment-refractory patients Researchers report framework for psychosurgery in treatment-refractory cases
This narrative critical review synthesizes contemporary psychosurgery options for treatment-refractory psychiatric disorders.
A new framework proposes connectomic-guided psychosurgery for treatment-refractory OCD, depression, and related disorders, based on symptom …
Frontiers Apr 23, 2026
Systematic review links CNTN6 gene to neurodevelopmental and mental disorders
Neurology Sys. Review
Systematic review links CNTN6 gene to neurodevelopmental and mental disorders This Brain Protein Might Explain Autism and Schizophrenia
This systematic review summarizes evidence on CNTN6 gene involvement in neurodevelopment and disease.
Scientists have identified a specific protein that helps wire the brain and may be linked to mental health conditions.
Frontiers Apr 23, 2026

Questions about Schizophrenia

Will taking semaglutide help improve my physical quality of life if I have schizophrenia and prediabetes?

Semaglutide can improve physical quality of life in people with schizophrenia and prediabetes, likely by helping with weight loss and metabolic health.

Full answer →
What does the research say about psychosis rates in people with bipolar disorder?

A large meta-analysis found that about 47% of people with bipolar disorder experience mood-incongruent psychosis, and psychotic symptoms are common, especially in bipolar I disorder.

Full answer →
Is there a link between schizophrenia and higher heart rate based on recent studies?

Yes, recent studies show people with schizophrenia tend to have a higher resting heart rate, which may contribute to their increased risk of sudden cardiac death.

Full answer →
Do GLP-1 drugs help reduce weight and sugar levels in severe mental illness?

Yes, GLP-1 drugs significantly reduce weight and HbA1c in people with severe mental illness, with low dropout rates, but benefits may fade after stopping.

Full answer →
Will taking cariprazine help me lose weight if I previously used olanzapine?

Yes, switching from olanzapine to cariprazine may help you lose weight, based on a 12-week study showing modest weight reduction compared to aripiprazole.

Full answer →
Does having schizophrenia increase the risk of heart problems like high heart rate?

Yes, schizophrenia is linked to a higher resting heart rate and increased risk of heart rhythm problems, according to a large meta-analysis.

Full answer →
Can the new monthly injection Perseris be used to treat adult schizophrenia?

Yes, Perseris (risperidone) is FDA-approved for once-monthly subcutaneous injection to treat schizophrenia in adults.

Full answer →
See all 7 questions about Schizophrenia →